Novel Capsid Inhibitor Approved for Super-Refractory HIV
The FDA approved lenacapavir (Sunlenca) in combination with antiretroviral therapy (ART) for heavily pretreated HIV-1 patients with drug-resistant infections, and for those who cannot tolerate other available options. Lenacapavir, a first-in-class long-acting HIV capsid inhibitor, is initially administered via oral tablets (300 mg) and subcutaneous shots (463.5 mg/1.5 mL), which are then followed by maintenance […]
Start HIV Antiretroviral Therapy ASAP, Experts Urge
WASHINGTON — Early initiation of antiretroviral therapy (ART) in patients with HIV can lead to better outcomes, especially for those ages 35 and younger, a follow-up analysis of the START trial showed. For patients who had deferred ART until their CD4 counts were below 350 cells/mm3, there was a 21% higher risk of death or […]
New study reveals why HIV remains in human tissue even after antiretroviral therapy: Discovery could open the door to new treatments that improve our immune system’s ability to eliminate the stubborn virus, lead to strides in MS research.
Thanks to antiretroviral therapy, HIV infection is no longer the life sentence it once was. But despite the effectiveness of drugs to manage and treat the virus, it can never be fully eliminated from the human body, lingering in some cells deep in different human tissues where it goes unnoticed by the immune system. Now, […]